# Safety, Tolerability and Clinical Activity of ASM-024 in Stable Moderate Asthma

> **NCT01190826** · PHASE2 · COMPLETED · sponsor: **Asmacure Ltée** · enrollment: 20 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** ASM-024
- **DRUG:** ASM-024 100 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01190826
- **Lead sponsor:** Asmacure Ltée
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2011-12
- **Final completion:** 2012-02
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2012-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01190826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01190826, "Safety, Tolerability and Clinical Activity of ASM-024 in Stable Moderate Asthma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01190826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*